WO1997016542A1 - Diagnostics and treatments of periodontal disease - Google Patents
Diagnostics and treatments of periodontal disease Download PDFInfo
- Publication number
- WO1997016542A1 WO1997016542A1 PCT/AU1996/000673 AU9600673W WO9716542A1 WO 1997016542 A1 WO1997016542 A1 WO 1997016542A1 AU 9600673 W AU9600673 W AU 9600673W WO 9716542 A1 WO9716542 A1 WO 9716542A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- complex
- prtr
- prtk
- ofthe
- gingivalis
- Prior art date
Links
- 208000028169 periodontal disease Diseases 0.000 title abstract description 9
- 238000011282 treatment Methods 0.000 title abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 119
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 86
- 241000605862 Porphyromonas gingivalis Species 0.000 claims abstract description 85
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000004472 Lysine Substances 0.000 claims abstract description 23
- 239000004475 Arginine Substances 0.000 claims abstract description 17
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 17
- 230000000890 antigenic effect Effects 0.000 claims abstract description 13
- 108010059378 Endopeptidases Proteins 0.000 claims abstract description 12
- 102000005593 Endopeptidases Human genes 0.000 claims abstract description 12
- 229940066758 endopeptidases Drugs 0.000 claims abstract description 8
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims abstract description 8
- 230000005875 antibody response Effects 0.000 claims abstract description 3
- 125000003396 thiol group Chemical class [H]S* 0.000 claims abstract 5
- 239000000203 mixture Substances 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 29
- 239000002671 adjuvant Substances 0.000 claims description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 101001027496 Porphyromonas gingivalis Lys-gingipain W83 Proteins 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 11
- 239000002324 mouth wash Substances 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 239000000551 dentifrice Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 229940051866 mouthwash Drugs 0.000 claims description 7
- 230000003647 oxidation Effects 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 75
- 238000001514 detection method Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 68
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 59
- 239000000872 buffer Substances 0.000 description 46
- 230000002797 proteolythic effect Effects 0.000 description 37
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 35
- 229960005486 vaccine Drugs 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 34
- 102000053602 DNA Human genes 0.000 description 34
- 239000011780 sodium chloride Substances 0.000 description 30
- 239000013598 vector Substances 0.000 description 29
- 241000894006 Bacteria Species 0.000 description 28
- 239000000463 material Substances 0.000 description 26
- 229920002684 Sepharose Polymers 0.000 description 25
- 230000003024 amidolytic effect Effects 0.000 description 23
- 229960003646 lysine Drugs 0.000 description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 239000000427 antigen Substances 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 238000002523 gelfiltration Methods 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 19
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- 102000035195 Peptidases Human genes 0.000 description 17
- 108091005804 Peptidases Proteins 0.000 description 17
- 239000000499 gel Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 101100342162 Porphyromonas gingivalis kgp gene Proteins 0.000 description 15
- 229960003121 arginine Drugs 0.000 description 15
- 238000002649 immunization Methods 0.000 description 15
- 239000000606 toothpaste Substances 0.000 description 15
- -1 adhesins Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 230000003053 immunization Effects 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 13
- 241000335876 Porphyromonas gingivalis W50 Species 0.000 description 13
- 229940034610 toothpaste Drugs 0.000 description 13
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 238000005349 anion exchange Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000003902 lesion Effects 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 210000000214 mouth Anatomy 0.000 description 12
- 235000019833 protease Nutrition 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 230000002163 immunogen Effects 0.000 description 11
- 235000013336 milk Nutrition 0.000 description 11
- 239000008267 milk Substances 0.000 description 11
- 210000004080 milk Anatomy 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 10
- 230000001810 trypsinlike Effects 0.000 description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 9
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 9
- 101800001509 Large capsid protein Proteins 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 150000007523 nucleic acids Chemical group 0.000 description 9
- 201000001245 periodontitis Diseases 0.000 description 9
- 238000005498 polishing Methods 0.000 description 9
- 239000000600 sorbitol Substances 0.000 description 9
- 235000010356 sorbitol Nutrition 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 101100298851 Aspergillus oryzae (strain ATCC 42149 / RIB 40) prtT gene Proteins 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 101100298845 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) prtR gene Proteins 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 8
- 101150023726 degR gene Proteins 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 210000004201 immune sera Anatomy 0.000 description 8
- 229940042743 immune sera Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
- 241000283073 Equus caballus Species 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 229960001212 bacterial vaccine Drugs 0.000 description 7
- 239000005018 casein Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 125000001288 lysyl group Chemical group 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 241000700618 Vaccinia virus Species 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000003906 humectant Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 5
- 101000653197 Beet necrotic yellow vein virus (isolate Japan/S) Movement protein TGB3 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 108010041102 azocasein Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 5
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000000185 hemagglutinin Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 239000012901 Milli-Q water Substances 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 4
- 108010076039 Polyproteins Proteins 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 238000011026 diafiltration Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000002200 mouth mucosa Anatomy 0.000 description 4
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000002853 nucleic acid probe Substances 0.000 description 4
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 229960004854 viral vaccine Drugs 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 108010001682 Dextranase Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108050001049 Extracellular proteins Proteins 0.000 description 3
- 108091020100 Gingipain Cysteine Endopeptidases Proteins 0.000 description 3
- 101710154606 Hemagglutinin Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
- 208000005888 Periodontal Pocket Diseases 0.000 description 3
- 101710176177 Protein A56 Proteins 0.000 description 3
- 239000012614 Q-Sepharose Substances 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 description 3
- 101710097834 Thiol protease Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000006161 blood agar Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 208000034391 chronic adult periodontitis Diseases 0.000 description 3
- 208000001277 chronic periodontitis Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007859 condensation product Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 235000011837 pasties Nutrition 0.000 description 3
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 101150065453 prtR gene Proteins 0.000 description 3
- 238000005185 salting out Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000206575 Chondrus crispus Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 108010042889 Inulosucrase Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102100027612 Kallikrein-11 Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101710159910 Movement protein Proteins 0.000 description 2
- 101000723939 Mus musculus Transcription factor HIVEP3 Proteins 0.000 description 2
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 241000656145 Thyrsites atun Species 0.000 description 2
- 101710152431 Trypsin-like protease Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003855 balanced salt solution Substances 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000003366 colagenolytic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940025294 hemin Drugs 0.000 description 2
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940094522 laponite Drugs 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000005341 metaphosphate group Chemical group 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- YFZOUMNUDGGHIW-UHFFFAOYSA-M p-chloromercuribenzoic acid Chemical compound OC(=O)C1=CC=C([Hg]Cl)C=C1 YFZOUMNUDGGHIW-UHFFFAOYSA-M 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- LFJJOPDNPVFCNZ-UHFFFAOYSA-N 2-[hexadecanoyl(methyl)amino]acetic acid Chemical class CCCCCCCCCCCCCCCC(=O)N(C)CC(O)=O LFJJOPDNPVFCNZ-UHFFFAOYSA-N 0.000 description 1
- NGOZDSMNMIRDFP-UHFFFAOYSA-N 2-[methyl(tetradecanoyl)amino]acetic acid Chemical class CCCCCCCCCCCCCC(=O)N(C)CC(O)=O NGOZDSMNMIRDFP-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 101710144734 48 kDa protein Proteins 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000186045 Actinomyces naeslundii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 101001057129 Bacillus cereus Enterotoxin Proteins 0.000 description 1
- 108010071023 Bacterial Outer Membrane Proteins Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 108090000395 Cysteine Endopeptidases Proteins 0.000 description 1
- 102000003950 Cysteine Endopeptidases Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 239000005696 Diammonium phosphate Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 240000000896 Dyera costulata Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000957351 Homo sapiens Myc-associated zinc finger protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- FUJCRWPEOMXPAD-UHFFFAOYSA-N Li2O Inorganic materials [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 102100038750 Myc-associated zinc finger protein Human genes 0.000 description 1
- 101000700655 Mycobacterium leprae (strain TN) Serine-rich antigen Proteins 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N Na2O Inorganic materials [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 244000227633 Ocotea pretiosa Species 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- XCOJIVIDDFTHGB-UEUZTHOGSA-N Perillartine Chemical compound CC(=C)[C@H]1CCC(\C=N\O)=CC1 XCOJIVIDDFTHGB-UEUZTHOGSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100024147 Protein phosphatase 1 regulatory subunit 14A Human genes 0.000 description 1
- 102000001218 Rec A Recombinases Human genes 0.000 description 1
- 108010055016 Rec A Recombinases Proteins 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 102100022135 S-arrestin Human genes 0.000 description 1
- 101710117586 S-arrestin Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 229920006387 Vinylite Polymers 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052910 alkali metal silicate Inorganic materials 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000007474 bm medium Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 101150039352 can gene Proteins 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000012532 cell-free culture fluid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 229910002026 crystalline silica Inorganic materials 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- XUCJHNOBJLKZNU-UHFFFAOYSA-M dilithium;hydroxide Chemical compound [Li+].[Li+].[OH-] XUCJHNOBJLKZNU-UHFFFAOYSA-M 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AINBZKYUNWUTRE-UHFFFAOYSA-N ethanol;propan-2-ol Chemical compound CCO.CC(C)O AINBZKYUNWUTRE-UHFFFAOYSA-N 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 150000002193 fatty amides Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001759 immunoprophylactic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000013580 kinin cascade Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 101150073640 ompF gene Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000004261 periodontium Anatomy 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 108010083127 phage repressor proteins Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940032085 sucrose monolaurate Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- AZJYLVAUMGUUBL-UHFFFAOYSA-A u1qj22mc8e Chemical group [F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O=[Si]=O.O=[Si]=O.O=[Si]=O.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 AZJYLVAUMGUUBL-UHFFFAOYSA-A 0.000 description 1
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56955—Bacteria involved in periodontal diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention relates to the PrtR-PrtK cell suiface protein of Poiphyromonas gingivalis and in particular a multimeric cell associated protein complex comprising the PrtR and PrtK proteins
- the invention also relates to pharmaceutical compositions and associated agents based on said complex for the detection, prevention and treatment of Periodontal disease associated with P. gingivalis
- Periodontal diseases are bacterial-associated inflammatory diseases ofthe supporting tissues ofthe teeth and range from the relatively mild form of gingivitis, the non-specific, reversible inflammation of gingival tissue to the more aggressive forms of periodontitis which are characterised by the destruction ofthe tooth's supporting structures
- Periodontitis is associated with a subgingival infection ofa consortium of specific Gram-negative bacteria that leads to the destruction ofthe periodontium and is a major public health problem
- P. gingivalis As the recovery of this microorganism from adult periodontitis lesions can be up to 50% ofthe subgingival anaerobically cultivable flora, whereas P. gingivalis is rarely recovered, and then in low numbers, from healthy sites.
- P. gingivalis is a black-pigmented, anaerobic, asaccharolytic, proteolytic Gram-negative rod that obtains energy from the metabolism of specific amino acids.
- the microorganism has an absolute growth requirement for iron, preferentially in the form of haeme or its Fe(III) oxidation product haemin and when grown under conditions of excess haemin is highly virulent in experimental animals.
- a number of virulence factors have been implicated in the pathogenicity of P. gingivalis including the capsule, adhesins, cytotoxins and extracellular hydrolytic enzymes.
- proteases have received a great deal of attention for their ability to degrade a broad range of host proteins including structural proteins and others involved in defence
- the proteins that have been shown to be substrates for P. gingivalis proteolytic activity include collagen types 1 and IV, fibronectin, fibrinogen, laminin, complement and plasma clotting cascade proteins, ⁇ i-antitrypsin, ⁇ macroglobulin, antichymotrypsin, antithrombin III, antiplasmin, cystatin C, IgG and IgA
- the major proteolytic activities associated with this organism have been defined by substrate specificity and are "trypsin-like", that is cleavage on the carboxyl side of arginyl and lysyl residues and collagenolytic although other minor activities have been reported
- P. gingivalis trypsin-like proteolytic activity has been shown to degrade complement, generating biologically active C5a, impair the phagocytic and other functions of neutrophils by modifying surface receptors, and abrogate the clotting potential of fibrinogen prolonging plasma clotting time
- the trypsin-like proteolytic activity of P. gingivalis also generates Fc fragments from human IgGI stimulating the release of pro- inflammatory cytokines from mononuclear cells and is associated with vascular disruption and enhanced vascular permeation through the activation ofthe kallikrein- kinin cascade P.
- gingivalis H66 designated Arg-gingipain
- Arg-gingipain A similar arginine-specific thiol protease has been disclosed in JP 07135973 and the amino acid sequence disclosed in WO 9507286 and in Kirszbaum et al, 1995 [Biochem Biophys Res Comm 207424-431 ] Pike et al (1994) [J Biol Chem 269406- 11] have characterised a 60 kDa lysine-specific cysteine proteinase from the culture fluid of P.
- gingivalis H66 designated Lys-gingipain and the partial gene sequence for this enzyme was disclosed in WO 9511298 and fully disclosed in WO 9617936 However, prior to the development ofthe present invention it was unknown that there existed on the cell surface of P.
- the present invention consists in a substantially purified antigenic complex for use in raising an antibody response directed against Porphyromonas gingivalis, the complex comprising at least one multimeric protein complex of arginine-specific and lysine-specific thiol endopeptidases each containing at least one adhesin domain, the complex having a molecular weight of greater than about 200 kDa
- the multimeric protein complex is associated with virulent strains of Porphyromonas gingivalis, preferably has a molecular weight of about 294 to about 323 kDa and is preferably derived from P. gingivalis W50 It is also preferred that the multimeric protein complex is composed of 9 proteins These 9 proteins preferably have the following N-terminal sequences
- the 9 proteins are PrtK48, PrtR45, PrtR44, PrtK39, PrtK44, PrtR27, PrtR17, PrtK 15 and PrtR 15 as described herein
- the purified antigenic complex normally has enzymatic activity it is preferred in a number of uses the thiol endopeptidases are rendered inactive This may be achieved in a number of ways, for example by oxidation or by mutation It is presently preferred that the inactivation is by oxidation
- the multimeric protein complex is encoded by the DNA sequence shown in Figures 8B and 9B
- the present invention consists in a composition for use in eliciting an immune response directed against Porphyromonas gingivalis, the composition comprising an effective amount ofthe complex ofthe first aspect ofthe present invention and a suitable adjuvant and/or acceptable carrier
- the present invention consists in an antibody preparation comprising antibodies specifically directed against the complex ofthe first aspect ofthe present invention
- the antibodies may be polyclonal antibodies or monoclonal antibodies
- the present invention consists in a method of treating a subject suffering from Porphyromonas gingivalis infection, the method comprising administering to the subject an amount ofthe antibody preparation ofthe third aspect of the present invention effective to at least partially neutralize the PrtR-PrtK complex of Porphyromonas gingivalis
- the antibody preparation may be administered by any of a number of well known routes, however, it is presently preferred that the preparation is administered orally
- the present invention consists in a method of reducing the prospect of P. gingivalis infection in an individual and/or severity of disease, the method comprising administering to the individual an amount ofthe composition ofthe second aspect ofthe present invention effective to induce an immune response in the individual directed against P. gingivalis
- the present invention consists in a recombinant host cell, the host cell being transformed with a DNA sequence(s) encoding PrtR-PrtK operatively linked to control sequences such that under appropriate conditions the host cell expresses PrtR-PrtK
- the present invention is directed to novel DNA sequences involving PrtR-PrtK constructs and vectors including plasmid DNA, and viral DNA such as human viruses, animal viruses, insect viruses, or bacteriophages which can be used to direct the expression of PrtR-PrtK protein in appropriate host cells from which the expressed protein may be purified
- viral DNA such as human viruses, animal viruses, insect viruses, or bacteriophages
- Another aspect ofthe present invention provides methods for molecular cloning ofthe genes encoding the PrtR-PrtK complex
- the nucleic acid sequences ofthe present invention can be used in molecular diagnostic assays for P.
- PrtR-PrtK complex can be used as an immunogen in prophylactic and/or therapeutic vaccine formulations against pathogenic strains of P. gingivalis, whether the immunogen is chemically synthesized, purified from P.
- the genes encoding PrtR-PrtK may be inco ⁇ orated into a bacterial or viral vaccine comprising recombinant bacteria or virus which is engineered to produce PrtR-PrtK by itself, or in combination with immunogenic epitopes of other pathogenic microorganisms
- the genes encoding PrtR-PrtK operatively linked to one or more regulatory elements can be introduced directly into humans to express the PrtR-PrtK to elicit a protective immune response
- a vaccine can also be based upon a recombinant component ofa mutated PrtR- PrtK inco ⁇ orated into an appropriate vector and expressed in a suitable transformed host (eg.
- the vaccine can be based on an intra-oral recombinant bacterial vaccine, where the recombinant bacterium expressing an inactivated PrtR-PrtK is a commensal inhabitant ofthe oral cavity Unlike whole P. gingivalis cells or other previously prepared antigens based on fimbriae or the capsule the PrtR-PrtK complex ofthe invention or component parts thereof are safe and effective antigens for the preparation ofa vaccine for the prevention of P. g7//g7v ⁇ //. ⁇ -associated periodontal disease
- the invention therefore provides a range of recombinant products based on the PrtR-PrtK complex
- the invention also provides antibodies raised against the said PrtR-PrtK complex, herein called anti-PrtR-PrtK antibodies
- the antibodies may be blended into oral compositions such as toothpaste, mouthwash, toothpowders and liquid dentifrices, mouthwashes, troches, chewing gums, dental pastes, gingival massage creams, gargle tablets, dairy products and other foodstuffs
- the invention provides a method of diagnosis for the presence of P. gingivalis characterised by the use of any one or a combination of an antibody, antigen or nucleic acid probe as hereinbefore defined comprising the application of known techniques including for example, enzyme linked immunosorbent assay
- the invention also provides diagnostic kits comprising antibodies, antigens and/or nucleic acid probes as hereinbefore defined
- Fig. 1 Anion exchange FPLC of a P. gingivalis W50 sonicate The sonicate in TC buffer containing 50 mM NaCl was applied to a Hiload XK 16/10 Q sepharose column and eluted using a linear gradient from 0 - 100% buffer B over 90 min at a flow rate of 2 0 ml min '1 Fractions (6 ml) were assayed for proteolytic and amidolytic activity using azocasein, Bz-L-Arg-/?NA and Z-L-Lys-/?NA The amidolytic activity of each 6 ml fraction with Bz-L-Arg-pNA is shown by the histogram
- Fig. 2 Gel filtration FPLC of the pooled and concentrated fractions from Q sepharose anion exchange FPLC containing proteolytic/amidolytic activity Anion exchange fractions containing the major peak of proteolytic/amidolytic activity were pooled, equilibrated in TC buffer containing 150 mM NaCl, concentrated and divided into four aliquots and each then independently applied to a gel filtration column (Superose 12 HR 10/30) and eluted using the same buffer at a flow rate of 0 3 ml min '1 Fractions (0.5 ml) were assayed for proteolytic and amidolytic activity Bz-L-Arg-/?NA amidolytic activity is shown by the histogram Vo and Vt indicate the void and total volumes of the column respectively The elution volumes of the standard proteins thyroglobulin 667 kDa, catalase 232 kDa and aldolase 158 kDa are marked
- Arg-sepharose FPLC of the 300 kDa gel filtration peak exhibiting Arg- and Lys-specific proteolytic activity Gel filtration fractions containing the major peak of proteolytic activity (300 kDa) were pooled and applied to an arginine-sepharose column
- Fig. 6 SDS-PAGE (boiled/reduced conditions) of 200 mM lysine eluant from the Arg- sepharose FPLC Lane 1, Pharmacia molecular mass standards (M r shown in kDa) Lane 2, 200 mM lysine eluant from Arg-sepharose FPLC Silver stained gel Fig 7.
- Fig. 8a Schematic representation of the prtR gene
- the PrtR nascent polyprotein is composed of a leader sequence, a prosequence followed by the Arg-specific cysteine proteinase PrtR45, and the adhesins PrtR44, PrtR15, PrtR17 and PrtR27 all preceded by an arginyl or lysyl residue
- Fig. 8b Nucleotide sequence of prtR.
- Fig. 9a Schematic representation of the prtK gene
- the PrtK nascent polyprotein is composed of a leader sequence , a prosequence followed by the Lys-specific cysteine proteinase PrtK48, and the adhesins PrtK39, PrtK 15 and PrtK44 all preceded by an arginyl or lysyl residue
- ELISA titration of sera from 5 mice immunized twice with the PrtR-PrtK complex emulsified in Freund's Incomplete Adjuvant Test sera (TS 32-36) and pre- immune sera (PIS 32-36) were screened using P.
- gingivalis W50 sonicate as the adsorbed antigen
- Primary antibody dilutions of 1/100, 1/500, 1/2500 and 1/12500 were used Bound antibody was determined using horseradish peroxidase-conjugated goat anti-mouse antibody and 3, 3 ',5, 5' tetramethylbenezidine
- the reaction product was quantitated spectrophotometrically using a 450 nm interference filter in a plate reader and recorded as optical density (O D ) readings DETAILED DESCRIPTION OF THE INVENTION
- the intra-oral bacterium Porphyromonas gingivalis possesses on its cell surface major trypsin-like proteinases as a 294-323 kDa heterodimeric protein complex of Arg-specific and Lys-specific thiol endopeptidases with hemagglutinins (adhesins) herein designated the PrtR- PrtK complex
- PrtR-PrtK complex can be purified from P.
- the purified PrtR-PrtK complex is then used to generate antibodies using standard techniques
- the animals used for antibody generation can be rabbits, goats, chickens, sheep, horses, cows etc
- a high antibody titre against the PrtR-PrtK complex is detected by immunoassay the animals are bled or eggs or milk are collected and the serum prepared and/or antibody purified using standard techniques or monoclonal antibodies produced by fusing spleen cells with myeloma cells using standard techniques
- the antibody (immunoglobulin fraction) may be separated from the culture or ascites fluid, serum, milk or egg by salting out, gel filtration, ion exchange and/or affinity chromatography, and the like, with salting out being preferred In the salting out method the antiserum or the milk is saturated with ammonium sulphate to produce a precipitate,
- the amount ofthe above antibodies administered is 00001 -50 g kg/day and that the content of the above antibodies is 00002 - 10% by weight preferably 0002 -5% by weight ofthe composition
- the oral composition of this invention wliich contains the above-mentioned serum or milk antibody may be prepared and used in various forms applicable to the mouth such as dentifrice including toothpastes, toothpowders and liquid dentifrices, mouthwashes, troches, periodontal pocket irrigating devices, chewing gums, dental pastes, gingival massage creams, gargle tablets, dairy products and other foodstuffs
- the oral composition according to this invention may further include additional well known ingredients depending on the type and form ofa particular oral composition
- the oral composition may be substantially liquid in character, such as a mouthwash or rinse
- the vehicle is typically a water-alcohol mixture desirably including a humectant as described below
- the weight ratio of water to alcohol is in the range of from about 1 1 to about 20 1
- the total amount of water-alcohol mixture in this type of preparation is typically in the range of from about 70 to about 99 9% by weight ofthe preparation
- the alcohol is typically ethanol or isopropanol Ethanol is preferred
- the pH of such liquid and other preparations ofthe invention is generally in the range of from about 4 5 to about 9 and typically from about 5 5 to 8
- the pH is preferably in the range of from about 6 to about 8 0, preferably 7 4
- the pH can be controlled with acid (e g citric acid or benzoic acid) or base (e g sodium hydroxide) or buffered (as with sodium citrate, benzoate, carbonate, or bicarbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, etc)
- the oral composition may be substantially solid or pasty m character, such as toothpowder, a dental tablet or a dentifrice, that is a toothpaste (dental cream) or gel dentifrice
- the vehicle of such solid or pasty oral preparations generally contains dentally acceptable polishing material
- polishing materials are water-insoluble sodium metaphosphate, potassium metaphosphate, tricalcium phosphate, dihydrated calcium phosphate, anhydrous dicalcium phosphate, calcium pyrophosphate, magnesium orthophosphate, trimagnesium phosphate, calcium carbonate, hydrated alumina, calcined alumina, aluminium silicate, zirconium silicate, silica, bentonite, and mixtures thereof
- Other suitable polishing material include the particulate thermosetting resins such as melamine-, phenolic, and urea-formaldehydes, and cross-linked polyepoxides and polyesters
- Preferred polishing materials include crystalline silica having particle sized of up to about 5 microns
- a polishing agent of colloidal silica such as those sold under the trademark SYLOID as Syloid 72 and Syloid 74 or under the trademark
- alkali metal alumino-silicate complexes are particularly useful since they have refractive indices close to the refractive indices of gelling agent-liquid (including water and/or humectant) systems commonly used in dentifrices.
- insoluble sodium metaphosphate may be formed in any suitable manner as illustrated by Tho ⁇ e's Dictionary of Applied Chemistry, Volume 9, 4th Edition, pp. 510-511.
- the forms of insoluble sodium metaphosphate known as Madrell's salt and Kurrol's salt are further examples of suitable materials.
- These metaphosphate salts exhibit only a minute solubility in water, and therefore are commonly referred to as insoluble metaphosphates (IMP).
- IMP insoluble metaphosphates
- impurities usually a few percent such as up to 4% by weight.
- the amount of soluble phosphate material which is believed to include a soluble sodium trimetaphosphate in the case of insoluble metaphosphate, may be reduced or eliminated by washing with water if desired.
- the insoluble alkali metal metaphosphate is typically employed in powder form of a particle size such that no more than 1% ofthe material is larger than 37 microns
- the polishing material is generally present in the solid or pasty compositions in weight concentrations of about 10% to about 99%. Preferably, it is present in amounts from about 10% to about 75% in toothpaste, and from about 70% to about 99% in toothpowder. In toothpastes, when the polishing material is silicious in nature, it is generally present in amount of about 10-30% by weight. Other polishing materials are typically present in amount of about 30-75% by weight.
- the liquid vehicle may comprise water and humectant typically in an amount ranging from about 10% to about 80% by weight ofthe preparation.
- humectant typically in an amount ranging from about 10% to about 80% by weight ofthe preparation.
- Glycerine, propylene glycol, sorbitol and polypropylene glycol exemplify suitable humectants/carriers.
- liquid mixtures of water, glycerine and sorbitol are particularly advantageous. In clear gels where the refractive index is an important consideration, about 2.5 - 30% w/w of water, 0 to about 70% w/w of glycerine and about 20-80% w/w of sorbitol are preferably employed.
- Toothpaste, creams and gels typically contain a natural or synthetic thickener or gelling agent in proportions of about 0.1 to about 10, preferably about 0.5 to about 5% w/w.
- a suitable thickener is synthetic hectorite, a synthetic colloidal magnesium alkali metal silicate complex clay available for example as Laponite (e.g. CP, SP 2002, D) marketed by Laporte Industries Limited.
- Laponite D is, approximately by weight 58.00% SiO 2 , 25.40% MgO, 3.05% Na 2 O, 0.98% Li 2 O, and some water and trace metals. Its true specific gravity is 2.53 and it has an apparent bulk density of 1.0 g/ml at 8% moisture.
- thickeners include Irish moss, iota carrageenan, gum tragacanth, starch, polyvinylpyrrolidone, hydroxyethylpropylcellulose, hydroxybutyl methyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose (e.g. available as Natrosol), sodium carboxymethyl cellulose, and colloidal silica such as finely ground Syloid (e.g. 244).
- Irish moss iota carrageenan
- gum tragacanth starch
- polyvinylpyrrolidone hydroxyethylpropylcellulose
- hydroxybutyl methyl cellulose hydroxypropyl methyl cellulose
- sodium carboxymethyl cellulose hydroxyethyl cellulose
- colloidal silica such as finely ground Syloid (e.g. 244).
- Solubilizing agents may also be included such as humectant polyols such propylene glycol, dipropylene glycol and hexylene glycol, cellosolves such as methyl cellosolve and ethyl cellosolve, vegetable oils and waxes containing at least about 12 carbons in a straight chain such as olive oil, castor oil and petrolatum and esters such as amyl acetate, ethyl acetate and benzyl benzoate.
- humectant polyols such propylene glycol, dipropylene glycol and hexylene glycol
- cellosolves such as methyl cellosolve and ethyl cellosolve
- vegetable oils and waxes containing at least about 12 carbons in a straight chain such as olive oil, castor oil and petrolatum and esters such as amyl acetate, ethyl acetate and benzyl benzoate.
- ajar of mouthrinse will have a label describing it, in substance, as a mouthrinse or mouthwash and having directions for its use, and a toothpaste, cream or gel will usually be in a collapsible tube, typically aluminium, lined lead or plastic, or other squeeze, pump or pressurised dispenser for metering out the contents, having a label describing it, in substance, as a toothpaste, gel or dental cream.
- Organic surface-active agents are used in the compositions ofthe present invention to achieve increased prophylactic action, assist in achieving thorough and complete dispersion ofthe active agent throughout the oral cavity, and render the instant compositions more cosmetically acceptable.
- the organic surface-active material is preferably anionic, nonionic or ampholytic in nature which does not denature the antibody ofthe invention, and it is preferred to employ as the surface-active agent a detersive material which imparts to the composition detersive and foaming properties while not denaturing the antibody
- anionic surfactants are water-soluble salts of higher fatty acid monoglyceride monosulfates, such as the sodium salt ofthe monosulfated monoglyceride of hydrogenated coconut oil fatty acids, higher alkyl sulfates such as sodium lauryl sulfate, alkyl aryl sulfonates such as sodium dodecyl benzene sulfonate, higher alkylsulfo-acetates, higher fatty acid esters of 1,2-
- Examples ofthe last mentioned amides are N-lauroyl sarcosine, and the sodium, potassium, and ethanolamine salts of N-lauroyl, N-myristoyl, or N-palmitoyl sarcosine which should be substantially free from soap or similar higher fatty acid material
- the use of these sarconite compounds in the oral compositions ofthe present invention is particularly advantageous since these materials exhibit a prolonged marked effect in the inhibition of acid formation in the oral cavity due to carbohydrates breakdown in addition to exerting some reduction in the solubility of tooth enamel in acid solutions.
- Examples of water-soluble nonionic surfactants suitable for use with antibodies are condensation products of ethylene oxide with various reactive hydrogen- containing compounds reactive therewith having long hydrophobic chains (e.g.
- condensation products contain hydrophilic polyoxyethylene moieties, such as condensation products of poly (ethylene oxide) with fatty acids, fatty alcohols, fatty amides, polyhydric alcohols (e.g sorbitan monostearate) and polypropyleneoxide (e.g. Pluronic materials)
- Surface active agent is typically present in amount of about 0.1-5% by weight. It is noteworthy, that the surface active agent may assist in the dissolving ofthe antibody ofthe invention and thereby diminish the amount of solubilizing humectant needed.
- Various other materials may be inco ⁇ orated in the oral preparations of this invention such as whitening agents, preservatives, silicones, chlorophyll compounds and/or ammoniated material such as urea, diammonium phosphate, and mixtures thereof
- whitening agents such as whitening agents, preservatives, silicones, chlorophyll compounds and/or ammoniated material such as urea, diammonium phosphate, and mixtures thereof
- silicones such as urea, diammonium phosphate, and mixtures thereof
- ammoniated material such as urea, diammonium phosphate, and mixtures thereof
- flavouring or sweetening material may also be employed.
- suitable flavouring constituents are flavouring oils, e.g. oil of spearmint, peppermint, wintergreen, sassafras, clove, sage, eucalyptus, marjoram, cinnamon, lemon, and orange, and methyl salicylate.
- suitable sweetening agents include sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclamate, perillartine, AMP (aspartyl phenyl alanine, methyl ester), saccharine, and the like
- flavour and sweetening agents may each or together comprise from about 0 1% to 5% more ofthe preparation.
- an oral composition according to this invention such as mouthwash or dentifrice containing the composition ofthe present invention is preferably applied regularly to the gums and teeth, such as every day or every second or third day or preferably from 1 to 3 times daily, at a pH of about 4 5 to about 9, generally about 5 5 to about 8, preferably about 6 to 8, for at least 2 weeks up to 8 weeks or more up to a lifetime
- compositions of this invention can be incorporated in lozenges, or in chewing gum or other products, e.g by stirring into a warm gum base or coating the outer surface ofa gum base, illustrative of which may be mentioned jelutong, rubber latex, vinylite resins, etc , desirably with conventional plasticisers or softeners, sugar or other sweeteners or such as glucose, sorbitol and the like
- composition of this invention also includes targeted delivery vehicles such as periodontal pocket irrigation devices, collagen, elastin, or synthetic sponges, membranes or fibres placed in the periodontal pocket or used as a barrier membrane or applied directly to the tooth root
- targeted delivery vehicles such as periodontal pocket irrigation devices, collagen, elastin, or synthetic sponges, membranes or fibres placed in the periodontal pocket or used as a barrier membrane or applied directly to the tooth root
- Another important form ofthe invention is a composition for use in eliciting an immune response directed against Porphyromonas gingivalis based on the PrtR-PrtK complex and suitable adjuvant delivered by nasal spray, orally or by injection to produce a specific immune response against the PrtR-PrtK complex thereby reducing colonisation of P. gingivalis and neutralising the PrtR-PrtK thereby preventing disease Due to the potent enzymatic activity ofthe complex typically the complex will be inactivated
- a vaccine can also be based upon a recombinant component ofthe PrtR-PrtK inco ⁇ orated into an appropriate vector and expressed in a suitable transformed host (eg E.
- PrtR-PrtK complex is a safe and effective antigens for the preparation of a composition for use in the prevention of P.
- the PrtR-PrtK complex can be produced using recombinant DNA methods as illustrated herein, or can be synthesized chemically from the amino acid sequence disclosed in the present invention Additionally, according to the present invention, the PrtR- PrtK complex may be used to generate antisera useful for passive immunization against periodontal disease and infections caused by P.
- adjuvants are used in conjunction with vaccine formulations
- the adjuvants aid by modulating the immune response and in attaining a more durable and higher level of immunity using smaller amounts of vaccine antigen or fewer doses than if the vaccine antigen were administered alone
- adjuvants include incomplete Freund's adjuvant (IF A), Adjuvant 65 (containing peanut oil, mannide monooleate and aluminium monostrearate), oil emulsions, Ribi adjuvant, the pluronic polyols, polyamines, Avridine, Quil A, saponin, MPL, QS-21, and mineral gels such as aluminium salts
- Other examples include oil in water emulsions such as SAF-1, SAF-0, MF59, Seppic ISA720, and other particulate adjuvants such as ISCOMs and ISCOM matrix
- An extensive but not exhaustive list of other examples of adjuvants are listed in Cox and Coulter 1992 [In Wong WK (ed ) Animals parasite control
- the preparation is combined with a mucosal adjuvant and administered via the oral route
- mucosal adjuvants are cholera toxin and heat labile E. coli toxin, the non-toxic B subunits of these toxins, genetic mutants of these toxins which have a reduced toxicity
- Other methods which may be utilised to deliver the PrtR-PrtK complex orally include incorporation ofthe protease into particles of biodegradable polymers (such as acrylates or polyesters) by microencapsulation to aid uptake ofthe microspheres from the gastrointestinal tract and to protect degradation ofthe proteins Liposomes, ISCOMs, hydrogels are examples of other potential methods which may be further enhanced by the incorporation of targeting molecules such as LTB, CTB or lectins for delivery ofthe PrtR-PrtK complex to the mucosal immune system
- the vaccine may include conventional pharmaceutically acceptable carriers, excipients, fillers,
- Another mode of this embodiment provides for either a live recombinant viral vaccine, recombinant bacterial vaccine, recombinant attenuated bacterial vaccine, or an inactivated recombinant viral vaccine which is used to protect against infections caused by P.
- gingivalis Vaccinia virus is the best known example, in the art, of an infectious virus that is engineered to express vaccine antigens derived from other organisms
- the recombinant live vaccinia virus which is attenuated or otherwise treated so that it does not cause disease by itself, is used to immunize the host
- Subsequent replication ofthe recombinant virus within the host provides a continual stimulation ofthe immune system with the vaccine antigens such as PrtR-PrtK complex, thereby providing long lasting immunity
- live vaccine vectors include adenovirus, cytomegalovirus, and preferably the poxviruses such as vaccinia (Paoletti and Panicali, U S Patent No 4,603,112) and attenuated Salmonella strains (Stocker et al , U S Patent Nos 5,210,035, 4,837,151, and 4,735,801, and Curtiss e/fl/ , 1988, Vaccine 6.155-160) Live vaccines are particularly advantageous because they continually stimulate the immune system which can confer substantially long-lasting immunity When the immune response is protective against subsequent P. gingi lis infection, the live vaccine itself may be used in a preventive vaccine against P.
- poxviruses such as vaccinia (Paoletti and Panicali, U S Patent No 4,603,112) and attenuated Salmonella strains (Stocker et al , U S Patent Nos 5,210,035, 4,837,151, and 4,735,801, and Curtiss e/f
- the live vaccine can be based on a bacterium that is a commensal inhabitant ofthe oral cavity
- This bacterium can be transformed with a vector carrying a recombinant inactivated PrtR-PrtK and then used to colonise the oral cavity, in particular the oral mucosa
- the expression ofthe recombinant protein will stimulate the mucosal associated lymphoid tissue to produce neutralising antibodies
- the genes encoding the PrtR-PrtK may be inserted into the vaccinia virus genomic DNA at a site which allows for expression of epitopes but does not negatively affect the growth or replication ofthe vaccinia virus vector
- the resultant recombinant virus can be used as the immunogen in a vaccine formulation
- the same methods can be used to construct an inactivated recombinant viral vaccine formulation except that the recombinant virus is inactivated, such as by chemical means known in the art, prior to use
- genetic material is used directly as the vaccine formulation
- Nucleic acid (DNA or RNA) containing sequences encoding the PrtR-PrtK protein complex operatively linked to one or more regulatory elements can be introduced directly to vaccinate the individual ("direct gene transfer") against pathogenic strains of P.
- gingivalis Direct gene transfer into a vaccinated individual, resulting in expression ofthe genetic material by the vaccinated individual's cells such as vascular endothelial cells as well as the tissue ofthe major organs, has been demonstrated by techniques in the art such as by injecting intravenously an expression plasmid cationic liposome complex (Zhu et al , 1993, Science 261 209-211 )
- Other effective methods for delivering vector DNA into a target cell are known in the art
- purified recombinant plasmid DNA containing viral genes has been used to inoculate (whether parentally, mucosally, or via gene-gun immunization) vaccines to induce a protective immune response (Fynan et al 1993, Proc Natl Acad Sci USA 90 11478-11482)
- cells removed from an individual can be transfected or electroporated by standard procedures known in the art, resulting in the introduction ofthe recombinant vector DNA into the target cell Cells
- immunization may be passive, i e immunization comprising administration of purified immunoglobulin containing antibody against PrtR-PrtK
- the present invention further provides the nucleotide sequence ofthe genes encoding the PrtR-PrtK complex, as well as the amino acid sequence deduced from the isolated genes
- the genes encoding the PrtR-PrtK complex are inco ⁇ orated into an expression vector, and the recombinant vector is introduced into an appropriate host cell thereby directing the expression of these sequences in that particular host cell
- the expression system comprising the recombinant vector introduced into the host cell, can be used (a) to produce PrtR-PrtK complex which can be purified for use as an immunogen in vaccine formulations, (b) to produce PrtR-PrtK complex to be used as an antigen for diagnostic immunoassays or for generating P.
- the recombinant expression vector is a live virus such as vaccinia virus
- the vector itself may be used as a live or inactivated vaccine preparation to be introduced into the host's cells for expression of PrtR-PrtK complex
- the recombinant bacterial vaccine can be based on a commensal inhabitant ofthe human oral cavity or animal if the vaccine is to prevent periodontal disease in animals
- the recombinant bacterial vaccine expressing inactivated PrtR-PrtK can be used to colonise the oral cavity, supragingival or subgingival plaque
- PrtR-PrtK which include, but are not limited to bacteria transformed with a bacteriophage vector, plasmid vector, or cosmid DNA; yeast containing yeast vectors; fungi containing fiingal vectors, insect cell lines infected with virus (e.g baculovirus); and mammalian cell lines transfected with plasmid or viral expression vectors, or infected with recombinant virus (e.g vaccinia virus, adenovirus, adeno-associated virus, retrovirus, etc )
- promoters and enhancers can be inco ⁇ orated into the vector or the DNA sequence encoding PrtR-PrtK to increase the expression ofthe PrtR-PrtK amino acid sequences, provided that the increased expression of the amino acid sequences is compatible with (for example, non-toxic to) the particular host cell system used.
- the DNA can be fused to DNA encoding other antigens, such as other bacterial outer membrane proteins, or other bacterial, fiingal, parasitic, or viral antigens to create a genetically fused (sharing a common peptide backbone) multivalent antigen for use as an improved vaccine composition
- the selection ofthe promoter will depend on the expression system used. Promoters vary in strength, i.e. ability to facilitate transcription. Generally, for the pu ⁇ ose of expressing a cloned gene, it is desirable to use a strong promoter in order to obtain a high level of transcription ofthe gene and expression into gene product. For example, bacterial, phage, or plasmid promoters known in the art from which a high level of transcription have been observed in a host cell system comprising E.
- coli include the lac promoter, t ⁇ promoter, rec A promoter, ribosomal RNA promoter, the P R and P L promoters, lacUV5, ompF, bla, lpp, and the like, may be used to provide transcription ofthe inserted DNA sequence encoding PrtR-PrtK.
- PrtR-PrtK protein may be lethal or detrimental to the host cells
- the host cell strain/line and expression vectors may be chosen such that the action ofthe promoter is inhibited until specifically induced.
- the addition of specific inducers is necessary for efficient transcription ofthe inserted DNA (e g , the lac operon is induced by the addition of lactose or isopropylthio-beta-D-galactoside).
- a variety of operons such as the t ⁇ operon, are under different control mechanisms The t ⁇ operon is induced when tryptophan is absent in the growth media
- the P promoter can be induced by an increase in temperature of host cells containing a temperature sensitive lambda repressor.
- expression of recombinant PrtR-PrtK protein may be controlled by culturing transformed or transfected cells under conditions such that the promoter controlling the expression from the inserted DNA encoding PrtR-PrtK amino acid sequences is not induced, and when the cells reach a suitable density in the growth medium, the promoter can be induced for expression from the inserted DNA
- Enhancer sequences are DNA elements that appear to increase transcriptional efficiency in a manner relatively independent of their position and orientation with respect to a nearby gene. Thus, depending on the host cell expression vector system used, an enhancer may be placed either upstream or downstream from the inserted DNA sequences encoding PrtR-PrtK amino acid sequences to increase transcriptional efficiency. These or other regulatory sites, such as transcription or translation initiation signals, can be used to regulate the expression ofthe gene encoding PrtR-PrtK Such regulatory elements may be inserted into DNA sequences encoding PrtR-PrtK amino acid sequences or nearby vector DNA sequences using recombinant DNA methods described herein for insertion of DNA sequences
- P. gingivalis nucleotide sequences containing regions encoding for PrtR-PrtK can be ligated into an expression vector at a specific site in relation to the vector's promoter, control, and regulatory elements so that when the recombinant vector is introduced into the host cell the P. ⁇ wgzr ⁇ s-specific DNA sequences can be expressed in the host cell
- the PrtR-PrtK specific DNA sequences containing their own regulatory elements can be ligated into an expression vector in a relation or orientation to the vector promoter and control elements which will allow for co-expression ofthe PrtR and PrtK.
- the recombinant vector is then introduced into the appropriate host cells, and the host cells are selected, and screened for those cells containing the recombinant vector Selection and screening may be accomplished by methods known in the art including detecting the expression of a marker gene (e.g , drug resistance marker) present in the plasmid, immunoscreening for production of PrtR-PrtK specific epitopes using antisera generated to PrtR-PrtK specific epitopes, and probing the DNA ofthe host's cells for PrtR-PrtK specific nucleotide sequence using one or more oligonucleotides and methods described herein
- a marker gene e.g , drug resistance marker
- Genetic engineering techniques may also be used to characterize, modify and/or adapt the encoded PrtR-PrtK protein For example, site-directed mutagenesis to inactivate the protease domains ofthe PrtR-PrtK and to modif the protein in regions outside the protective domains, may be desirable to increase the safety and solubility
- the host organism for the vector containing the PrtR-PrtK genes and constructs can be a commensal inhabitant ofthe oral cavity; for example an inhabitant of subgingival plaque, supragingival plaque or a bacterium associated with the oral mucosa
- commensal intra-oral bacteria would be Streptococcus species and Actinomyces species, eg Streptococcus salivarius, Streptococcus sanguis, Actinomyces naeslundii.
- the DNA encoding the PrtR-PrtK could be linked with DNA encoding leader sequences of extracellular proteins of these commensal intra-oral bacteria
- the DNA encoding the PrtR-PrtK could also be linked with, or inserted into, the DNA encoding extracellular proteins to produce secreted fusion proteins
- Examples of extracellular proteins that could be used to produce fusion proteins with the inactivated PrtR-PrtK could be the glucosyltranferases (GTF) or fructosyltransferases (FTF)
- GTF glucosyltranferases
- FTF fructosyltransferases
- the nucleic acid sequences ofthe present invention can be used in molecular diagnostic assays for detecting P. gingivalis genetic material
- PrtR-PrtK sequence-specific oligonucleotides can be synthesized for use as primers and/or probes in amplifying, and detecting amplified, nucleic acids from P.
- PCRTM polymerase chain reaction Cetus Co ⁇ oration
- DNA deoxyribonucleic acid
- RNA ribonucleic acid
- Nucleic acid probes that are capable of hybridization with specific gene sequences have been used successfully to detect specific pathogens in biological specimens at levels of sensitivity approaching IO 3 - IO 4 organisms per specimen (1990, Gene Probes for Bacteria, eds Macario and deMacario, Academic Press) Coupled with a method that allows for amplification of specific target DNA sequences, species-specific nucleic acid probes can greatly increase the level of sensitivity in detecting organisms in a clinical specimen Use of these probes may allow direct detection without relying on prior culture and/or conventional biochemical identification techniques This embodiment ofthe present invention is directed to pnmers which amplify species-specific sequences ofthe genes encoding PrtR-PrtK of P.
- DNA may be extracted from clinical specimens which may contain P. gingivalis using methods known in the art
- cells contained in the specimen may be washed in TE buffer and pelleted by centrifugation
- the cells then may be resuspended in 100 ul of amplification reaction buffer containing detergents and proteinase K
- the resultant sample may be composed ofthe cells in lOmM Tris pH 8 3, 50mM KCl, 1 5mM MgCl 2 , 0 01% gelatin, 045% NP40TM, 0 045% Tween 20TM, and 60 ug/ml proteinase K
- the sample is incubated in a 55°C water bath for 1 hour Following the incubation, the sample is incubated at 95°C for 10 minutes to heat-inactivate the proteinase K
- the sample may then be amplified in accordance with standard PCR protocols
- P. gingivalis W50 was grown anaerobically at 37°C on lysed horse blood agar and in modified BM media containing 1 ⁇ g/ml hemin Bacteria were maintained on lysed horse blood plates by routine passage ( ⁇ 10 passages) and used to inoculate batch cultures Batch culture growth in Brain Heart Infusion medium was monitored at 650 nm using a spectrophotometer (295E, Perkin-Elmer) Culture purity was checked routinely by Gram stain, microscopic examination and by using a variety of biochemical tests Stocks were maintained as lyophilised cultures A culture of P.
- gingivalis was grown to late logarithmic phase and the cells harvested by centrifugation (5,000 x g, 20 min, 4°C) and then resuspended in 160 ml TC buffer (20 mM Tris-HCl pH 7 4 and 5 mM CaCl 2 ) containing 50 mM NaCl and subjected to mild sonication using a Branson Sonifier 250 with an output control of 3 and a 50% duty cycle for 15 min at 4°C The sonicate was centrifuged (100,000 x ⁇ , 30 min, 4 °C) and the supernatant filtered (0.22 ⁇ m) prior to anion-exchange FPLC The sonicate was applied to an anion-exchange column (Hiload XK 16/10 Q Sepharose, Pharmacia-LKB) cooled to 4 °C, in multiple injections using a 50 ml superloop (Pharmacia-LKB) The sample was eluted using a linear gradient from 0 -
- Buffer A was TC buffer containing 50 mM NaCl and buffer B was TC buffer containing 500 mM NaCl Fractions were analysed for proteolytic and amidolytic activity using azocasein (A-2765, Sigma Chemical Co St Louis, MO), benzoyl-L-Arg- ?-nitroanilide (Bz-L-Arg-pNa, Sigma) and benzyloxycarbonyl-L-Lys- - nitroanilide (Z-L-Lys-/?Na, Calbiochem, Melbourne, Australia) vide infra Anion- exchange fractions containing the majority of proteolytic/amidolytic activity were pooled, washed and then concentrated in TC buffer containing 150 mM NaCl using a centricon 10 micro-concentrator (Amicon) The sample was then divided into four aliquots and each was independently applied to a gel filtration column (Superose 12, HR 10/30, Pharmacia-LKB
- the column was washed with 500 mM NaCl and re-equilibrated with TC buffer containing 50 mM NaCl
- the column was first eluted with 200 mM lysine-HCl pH 7.4 in TC buffer containing 50 mM NaCl at a flow rate of 0.1 ml min "1 .
- This was followed by 750 mM lysine-HCl pH 7.4 in the same buffer.
- the column was then re-equilibrated with TC buffer containing 50 mM NaCl and then eluted with 200 mM arginine-HCl pH 7.4 in TC buffer containing 50 mM NaCl at a flow rate of 0.1 ml min "1 .
- the unbound material collected was then re-applied to the Arg-sepharose column and the elution steps repeated. This sequence was repeated until all proteolytic activity had bound to the column.
- the eluant was monitored at 280 nm and peaks collected using a Frac 100 fraction collector.
- Buffer A was TC buffer containing 50 mM NaCl and 0.1% octyl- ⁇ -D-glucopyranoside and buffer B was TC buffer containing 500 mM NaCl and 0.1% octyl- ⁇ -D-glucopyranoside.
- the eluant was monitored at 280 nm and eluant peaks collected using a Frac 100 fraction collector.
- Azocasein, and z-L-lys- Na were used to routinely assay FPLC fractions for proteolytic and amidolytic activity.
- a sample of each fraction (20 - 200 :1) was incubated at 37 °C with azocasein (5 mg/ml final concentration) in TC buffer pH 8.0 containing 150 mM NaCl and 10 mM cysteine.
- azocasein the reaction was stopped by the addition of 30% trichloroacetic acid at 4 °C. Samples were centrifuged and the wo ofthe supernatant measured using a spectrophotometer (Perkin Elmer, model 552).
- SDS-PAGE was performed using a Mini protean II electrophoresis system (Biorad) with 12% (w/v), 1 mm separating gels, overlaid with 5% stacking gels (Laemmli, 1970) [Nature 277 680-685] Two volumes of each sample were mixed with one volume of buffer [0 5 M Tris-HCl, pH 6 8, 5% v/v 2-mercaptoethanol, 10 0% w/v SDS, 0 05% w/v bromophenol blue (75% v/v) and glycerol (25% v/v)] and heated to 100 °C for 4 min unless otherwise stated SDS-PAGE was performed at room temperature using a current of 30 - 50 mA and a potential difference of ⁇ 200 V For silver staining, gels were fixed in methanol/water/acetic acid (45/45/10, v/v/v), washed in Milli Q water, reduced with 5 ⁇ g/ml dithiothre
- the ultrasonication procedure was effective at releasing the cell-associated Arg- and Lys-specific proteolytic activity of P. gingivalis W50 and 15 min was required for maximal release of activity
- the sonicate of P. gingivalis W50 cells contained 0 30 mg ml "1 protein and 2 6 and 2 3 ⁇ mol min "1 mg protein "1 activity with 1 0 mM Bz-L-Arg- pNA and z-L-Lys-pNA as substrate respectively at 37 °C
- the crude sonicate was subjected to Q-sepharose anion exchange FPLC and a representative chromatogram is presented in Fig 1 Proteolytic/amidolytic activity eluted as one major peak between 246 - 320 mM NaCl (Fig 1) which was collected, concentrated using a centricon- 10 (Amicon) and then applied to the Superose 12 gel filtration column (Fig 2) Molecular mass gel filtration standards were used to determine the ofthe peaks obtained and
- the 300 kDa gel filtration protein complex was incubated with ⁇ , ⁇ -casein.
- the ⁇ , ⁇ -casein peptides released by the action ofthe proteolytic activity ofthe 300 kDa complex were purified by RP-HPLC and identified by amino acid composition and sequence analyses.
- the sites of ⁇ , ⁇ -casein cleavage by the material ofthe 300 kDa complex were the carboxyl side of arginyl and lysyl residues only (Fig 4). All arginyl and lysyl residues of ⁇ , ⁇ -casein were cleaved except the N-terminal Arg and the Lys residues flanking the Ser(P) cluster sequence, presumably due to the high negative charge density (Fig. 4).
- the 300 kDa complex was then applied to an Arg-sepharose column and washed with TC buffer containing 500 mM NaCl (Fig 5)
- the Arg- sepharose was eluted first with 200 mM lysine in TC buffer (Fig.
- the proteins eluted from the Arg-sepharose column with 200 mM lysine and 200 mM arginine were washed, concentrated and equilibrated with TC buffer containing 50 mM NaCl and 1 0% octyl- ⁇ -D-glucopyranoside and applied independently to a Mono Q anion exchange column Elution from the Mono Q column with a NaCl gradient associated the Arg-specific proteolytic activity with the 45 kDa protein with a 25 fold purification over the original crude sonicate (Table 2, Fig 7)
- the specificity ofthe 45 kDa proteinase for arginyl residues was confirmed by the enzyme cleaving Bz-L-Arg- pNA but not z-L-Lys-pNA
- the Arg-specific 45 kDa enzyme was activated by thiols (particularly cysteine), not inhibited by PMSF or AEBSF but inhibited by sulphydryl- directed
- the other proteins ofthe 300 kDa complex, the 48 kDa Lys-specific proteinase, the other 44 kDa protein and the 39 kDa and 15 Da proteins are encoded by a single gene the prtK presented schematically in Fig 9a
- the complete nucleotide sequence and deduced amino acid sequence ofthe PrtK is shown in Fig 9b
- the prtK is similar to the prtR in that it encodes a putative leader sequence, a prosequence followed by the proteinase domain which is then followed by sequence-related adhesins that have high homology with the C-terminal adhesins of the prtR
- the PrtK48 also has the same N- terminal sequence and enzyme characteristics as the 60 kDa Lys-specific endopeptidase previously purified from the culture fluid of P. gingivalis H66 by Pike et al (1994) [J Biol Chem 269 406-411 ] and designated Lys-gingipain
- the PrtK39, PrtK 15 and PrtK44 are all sequence-related and have high homology with the PrtR hemagglutinins/adhesins particularly the 15 kDa protein which is identical in both gene products suggesting that these proteins also are hemagglutinin/adhesins.
- PrtR-PrtK complexes As the 300 kDa proteinase-adhesin complex and higher molecular mass forms are composed of proteins from the two genes, the prtR and prtK, we suggest that they be designated PrtR-PrtK complexes.
- the deduced molecular mass ofthe mature PrtR is 160 kDa (Fig. 9a, b) and mature PrtK is 163 kDa (Fig.
- the characterization ofthe 300 kDa cell-associated complex as being composed of processed domains ofthe two genes the prtR and prtK suggests that the secreted, mature PrtR and PrtK proteins associate and then are processed, perhaps autolytically.
- the identification of several ofthe domains ofthe PrtR and PrtK in the culture supernatant by independent groups is consistent with the proteolytic (autolytic) processing of these polyproteins.
- As high material (0.6 - ; 2 x 10° Da) on gel filtration Fig.
- the partial dissociation ofthe complex on binding to substrate may be a mechanism by which the complex targets specific host macromolecules and cells releasing the proteinase/adhesin domains at the target site on binding
- This example describes the purification of a novel cell associated complex of Arg- specific and Lys-specific proteinases and sequence-related adhesins encoded by the two genes, the prtR and prtK
- P. gingivalis W50 was grown anaerobically at 37°C on lysed horse blood agar and in modified BM media containing 1 ⁇ g/ml hemin Bacteria were maintained on lysed horse blood plates by routine passage ( ⁇ 10 passages) and used to inoculate batch cultures Batch culture growth in Brain Heart Infusion medium was monitored at 650 nm using a spectrophotometer (295E, Perkin-Elmer) Culture purity was checked routinely by Gram stain, microscopic examination and by using a variety of biochemical tests Stocks were maintained as lyophilised cultures A culture of P.
- gingivalis was grown to late logarithmic phase and the cells harvested by centrifugation (5,000 x g, 20 min, 4°C) Chloroform was added to the cell pellet and after gentle mixing the suspension was left for 15 min at room temperature Following chloroform treatment, 20 mM Tris-HCl pH 8 0 buffer containing 50 mM NaCl was added and gently mixed This mixture was then centrifuged (100,000 x , 30 min, 4°C) and the supernatant diafiltered through a 100,000 M r cut-off membrane (Amicon) with five volumes of distilled water This purifies and inactivates by oxidation the 294-323 kDa PrtR-PrtK which is freeze dried and used as an immunogen The PrtR-PrtK purified by diafiltration was composed of 48, 45, 44, 39, 27, 17 and 15 kDa components as shown by SDS-PAGE (Fig 10)
- Polyclonal antiserum to PrtR-PrtK was raised in a rabbit by immunizing with the O 2 -inactivated PrtR-PrtK subcutaneously
- the rabbit was immunized at day 0 with 40 ⁇ g of protein in incomplete Freund's adjuvant, day 14 with 90 ⁇ g of protein in incomplete Freund's adjuvant, and day 28 with 60 ⁇ g of protein in incomplete Freund's adjuvant Immunizations were carried out using standard procedures
- Polyclonal antisera having a high titre against P. gingivalis was obtained If desired the antibodies directed specifically against P. gingivalis can be obtained using standard procedures
- This embodiment ofthe present invention is to provide PrtR-PrtK protein to be used in as an immunogen in a prophylactic and/or therapeutic vaccine for active immunization to protect against or treat infections caused by P. gingivalis
- an antigen of P. gingivalis comprising a bacterial protein should be immunogenic, and induce functional antibodies directed to one or more surface-exposed epitopes on intact bacteria, wherein the epitope(s) are conserved amongst strains of P. gingivalis
- the protein was purified from P. gingivalis using the method described herein in Example 1
- Mice were immunized with the purified inactivated PrtR-PrtK protein (25 ug) with adjuvant (20 ug of QS21) two times at four week intervals
- the purified PrtR-PrtK was inactivated by air oxidation Blood from the immunized mice was drawn 32 days after the last immunization and the immune sera was pooled The pooled immune sera was assayed against whole bacteria (P.
- PrtR-PrtK is the target of bactericidal antibody generated from immunization with the inactivated protein
- Polyclonal antiserum to PrtR- PrtK was raised in a rabbit by immunizing with the inactivated PrtR-PrtK subcutaneously
- a rabbit was immunized at day 0 with 40 ⁇ g of protein in incomplete Freund's adjuvant, day 14 with 90 ⁇ g of protein in incomplete Freund's adjuvant, and day 28 with 60 ⁇ g of protein in incomplete Freund's adjuvant
- the resultant antiserum was tested for its bactericidal activity against strain W50 of P.
- the bacteria were grown to logarithmic phase in brain-heart infusion (BHI) broth An aliquot ofthe bacterial culture was diluted to 5 x 10 4 colony forming units (CFU) per ml in 10% bovine serum albumin in a balanced salt solution
- the bactericidal assay reaction contained bacteria, polyclonal antiserum to inactivated PrtR- PrtK protein, a complement source consisting of normal human serum which was absorbed with protein G to remove antibodies, and the balanced salt solution All reagents were added to the reaction to yield a 250 ⁇ l volume Aliquots of 25 ⁇ l ofthe reaction were removed and plated in triplicate on BHI agar at times 0 and 60 minutes The plates were incubated and colonies were counted the next day The percent killing was calculated using the average ofthe three triplicate values at the 2 times A representative example of data generated by the bactericidal assays is shown in Table 4 The results indicate that the polyclonal antiserum raised to the inactivated Prt
- gingivalis strains from diverse clinical and geographical sources Bacteria from each culture were harvested by swabs and suspended in PBS to an optical absorbance of 1 0 at 600nm A microliter of each suspension was applied to a nitrocellulose membrane and allowed to dry The membrane was incubated one hour at room temperature in a solution of 5% non-fat dry milk in PBS to block the residual binding sites ofthe membrane The membrane was washed twice with PBS, and then immersed in the blocking solution containing the immune sera diluted to 1 1000 The membrane was incubated with the antibody overnight at 46°C with gentle shaking The membrane was washed three times with PBS and then incubated for 2 hours at room temperature with alkaline phosphatase conjugated recombinant protein G (1 1500 in PBS with 5% non-fat dry milk) The membrane was washed three times with PBS and bound antibody was detected by the addition of substrate The immune sera reacted with all strains as strongly, or to a greater extent than, strain W50 Thus, the antibodies elicited by imm
- PrtR-PrtK may be purified from a host containing a recombinant vector which expresses PrtR-PrtK
- hosts include, but are not limited to, bacterial transformants, yeast transformants, filamentous fungal transformants, and cultured cells that have been either infected or transfected with a vector which encodes PrtR-PrtK
- Many methods are known for the introduction ofa vaccine formulation into the human or animal to be vaccinated These include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, ocular, intranasal, and oral administration
- the vaccine may further comprise a physiological carrier such as a solution, a polymer or liposomes, and an adjuvant, or a combination thereof
- gingivalis W50 cells were prepared by incubating an aliquot of cells in 0 5% (vol/vol) of buffered formal saline overnight at 4°C
- the chloroform extract of P. gingivalis was prepared as detailed in Example 2
- Purification of PrtR-PrtK complex was performed as detailed in Example 1
- the PrtR-PrtK domains were prepared by taking the PrtR- PrtK complex and incubating in the presence of 50mM 2-mercaptoethanol for 8 h at 4°C This resulted in the breakdown ofthe PrtR-PrtK complex to domains that were 15-115 kDa proteins as shown by gel filtration FPLC and SDS-PAGE as performed in Example 1
- P. gingivalis cells were grown at 37°C on lysed horse blood agar (HBA) plates until day 3 or 4 in an anaerobic chamber (Mark 3 Anaerobic Workstation , Don Whitley Scientific Limited; with an air mixture of 8% H 2 , 12% CO 2 , 80% N 2 ), then passaged into 20ml of brain heart infusion broth (BHIB, Oxoid) supplemented with 0.5g/L cysteine and lmg/L haemin for 24 hours in a standard incubator at 37°C.
- HBA horse blood agar
- mice were marked for identification, their backs and chests shaved to make measurement of lesions possible, then weighed prior to inoculation with the challenge dose at a single site in the middle ofthe back A 0 1ml dose was given representing a predicted challenge dose of 3x10° bacteria per mouse.
- the inoculum dose was confirmed by culturing various dilutions ofthe challenge dose on lysed HBA plates and examining the number of colonies 7 days later
- mice were examined daily for the number and size of lesions on their body and their size estimated by measuring the approximate surface area in mm 2 involved
- Previous experiments had shown that in unimmunized mice, lesions developed on the belly ofthe mice following inoculation of live bacteria into the back or side Any distressed animals were culled Observations were carried out over two weeks and a summary of one such experiment is summarised below in Table 6 In this experiment while a dose of 3x10 9 bacteria per mouse was the desired number of bacteria, after plating out ofthe inoculum it was calculated that each mouse actually received a challenge dose of 3 17xl0 9 live P. gingivalis bacteria strain W50
- Bacterial strains P. gingivalis W50 was grown in modified BM medium supplemented with 1 ⁇ g/ml haemin in an atmosphere of 10% CO 2 , 10% H 2 and 80% N 2 at 37°C Escherichia coli JMl 09 and Escherichia coli LE392 were grown in LB medium at 37°C Escherichia coli strains harbouring pUC 18 plasmids were grown in LB medium supplemented with lOO ⁇ g/ml ampicillin at 37°C
- Chromosomal DNA was isolated from P. gingivalis W50 as described by Smith et al, [Oral Microbiol Immunol 4 47-51 (1989)] except that cells were pelleted from a 500ml late-exponential culture
- the genomic library was constructed from BamHI partially-digested W50 DNA which was partially-filled with dGTP and dATP and ligated into LambdaGEM ⁇ -H Xhol half-site arms (Promega) and packaged using Packagene ® (Promega).
- prtR gene characterisation The genomic library was screened using degenerate synthetic oligonucleotides derived from the N-terminal sequence information ofthe purified PrtR45 The oligonucleotide probes were based on the amino acid sequence YEGDIKD (antisense) and KDFVDWKNQ (sense) and were 5' end-labelled using ⁇ 32 P ATP and T4 polynucleotide kinase Approximately 1.5 x IO 4 phage were screened by lifting onto Nylon membrane filters and hybridised with radiolabeled oligonucleotides overnight in hybridisation buffer 6xSSC (SSC is 15mM sodium citrate, 150mM NaCl pH 8 0), 0.25% SDS, 5x Denhardt's solution and lOO ⁇ g/ml salmon sperm DNA at 44°C Filters were washed extensively in a solution of 5xSSC containing 0.01% SDS (w/v) at 44°C Positively-hybri
- prtK gene characterisation The 5' portion ofthe gene encoding PrtK was isolated from the same genomic library described above The genomic library was screened using a degenerate synthetic oligonucleotide derived from the N-terminal sequence information ofthe purified PrtK48. The oligonucleotide probes were sense to the amino acid sequence DVYTDHGD and radiolabelled as described above.
- Hybridisation and washing conditions were as described above except that the temperature was 48°C and the filters were washed extensively in a solution of 3xSSC containing 0.01% SDS (w/v) at 48°C Lambda clone 12 with an insert size of approximately 15kb was selected and digested with BamHI and a 3.3kb fragment was ligated into plasmid Zfar ⁇ HI-BAP pUC18 and Escherichia coli JMl 09 transformed with the recombinant plasmid as described previously.
- the 3 3 kb BamHI fragment contained the 5' portion of prtK which constituted the end ofthe lambda 12 clone Sequence characterisation ofthe 3 3kb BamHI fragment showed that the DNA sequence encoding PrtK48 contains an internal EcoRI site Subsequently, a second oligonucleotide probe (lysur) specific to the sequence THIGAH which is found within the PrtK48 was generated to determine a suitable strategy for cloning the 3 ' end of prtK.
- gingivalis EcoRI fragments was packaged using Gigapacklll Gold packaging extract (Stratagene) according to the manufacturer's instructions
- the library was screened as described previously, using oligonucleotide lysur except that hybridisation temperatures were 42°C and filters were washed to 3xSSC containing 0 01% SDS (w/v) at 42°C
- In vivo excision ofthe Lambda Zap II positive genomic clone was performed (Stratagene instruction manual) to excise the pBluescript phagemid which was subsequently sequenced to generate the sequence information corresponding to the 3 'end of the prtK gene
- Double-stranded plasmid template DNA prepared following the procedure of Li and Schweizer [Focus 15 19-20 (1993)] was sequenced in both directions using DNA sequence-derived, synthetic oligonucleotides, following the di ⁇ deoxy termination method [Proc Natl Acad Sci U S A 74 5463-5467 (1977)], using the Sequenase version 2 0 nucleotide sequencing kit purchased from United States Biochemicals Nucleotide and protein sequence data were analysed using programme suites accessed by the Australian National Genomic Information Service (ANGIS)
- ANGIS Australian National Genomic Information Service
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT96934198T ATE312909T1 (en) | 1995-10-30 | 1996-10-30 | DIAGNOSTICS AND TREATMENTS OF PERIDONTAL DISEASES |
US09/066,330 US6511666B1 (en) | 1995-10-30 | 1996-10-30 | Diagnostics and treatments of periodontal disease |
NZ320015A NZ320015A (en) | 1995-10-30 | 1996-10-30 | Purified antigenic complex for raising antibody response against porphyromonas gingivalis |
DE69635582T DE69635582T2 (en) | 1995-10-30 | 1996-10-30 | DIAGNOSTICS AND TREATMENTS OF PERIDONTAL DISEASES |
KR1019980703117A KR100286055B1 (en) | 1995-10-30 | 1996-10-30 | Diagnosis and Treatment of Periodontal Disease |
EP96934198A EP0858504B1 (en) | 1995-10-30 | 1996-10-30 | Diagnostics and treatments of periodontal disease |
AU72673/96A AU715456B2 (en) | 1995-10-30 | 1996-10-30 | Diagnostics and treatments of periodontal disease |
CA 2235224 CA2235224C (en) | 1995-10-30 | 1996-10-30 | Diagnostics and treatments of periodontal disease |
JP51691597A JP4117026B2 (en) | 1995-10-30 | 1996-10-30 | Diagnosis and treatment of periodontal disease |
US11/654,512 US20070189982A1 (en) | 1995-10-30 | 2007-01-18 | Diagnostics and treatments of Periodontal disease |
US13/064,286 US20110213129A1 (en) | 1995-10-30 | 2011-03-16 | Diagnostics and treatments of periodontal disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPN6275A AUPN627595A0 (en) | 1995-10-30 | 1995-10-30 | Diagnostics and treatments of periodontal disease |
AUPN6275 | 1995-10-30 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/229,066 Continuation US20030157637A1 (en) | 1995-10-30 | 2002-08-28 | Diagnostics and treatments of periodontal disease |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997016542A1 true WO1997016542A1 (en) | 1997-05-09 |
Family
ID=3790602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1996/000673 WO1997016542A1 (en) | 1995-10-30 | 1996-10-30 | Diagnostics and treatments of periodontal disease |
Country Status (12)
Country | Link |
---|---|
US (3) | US6511666B1 (en) |
EP (1) | EP0858504B1 (en) |
JP (1) | JP4117026B2 (en) |
KR (1) | KR100286055B1 (en) |
AT (1) | ATE312909T1 (en) |
AU (2) | AUPN627595A0 (en) |
DE (1) | DE69635582T2 (en) |
DK (1) | DK0858504T3 (en) |
ES (1) | ES2255082T3 (en) |
NZ (1) | NZ320015A (en) |
WO (1) | WO1997016542A1 (en) |
ZA (1) | ZA969130B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998049192A1 (en) * | 1997-04-30 | 1998-11-05 | The University Of Melbourne | SYNTHETIC PEPTIDE CONSTRUCTS FOR THE DIAGNOSIS AND TREATMENT OF PERIODONTITIS ASSOCIATED WITH $i(PORPHYROMONAS GINGIVALIS) |
EP1157033A1 (en) * | 1999-03-01 | 2001-11-28 | The University Of Melbourne | Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis |
EP1240191A1 (en) * | 1999-12-24 | 2002-09-18 | Csl Limited | P. gingivalis antigenic composition |
JP2003531634A (en) * | 2000-04-28 | 2003-10-28 | シーエスエル、リミテッド | Porphyromonas gingivalis recombinant protein and truncated product |
US6652875B1 (en) | 1998-07-29 | 2003-11-25 | Pacific Biolink Pty. Limited | Casein formulations for the delivery of bioactive constituents |
WO2006032104A1 (en) | 2004-09-23 | 2006-03-30 | The University Of Melbourne | Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection |
EP1908772A2 (en) | 1997-12-10 | 2008-04-09 | Csl Limited | Porphorymonas gingivalis polypeptides and polynucleotides |
WO2010022463A1 (en) * | 2008-08-29 | 2010-03-04 | Oral Health Australia Pty Ltd | Prevention, treatment and diagnosis of p.gingivalis infection |
AU2005287884B2 (en) * | 2004-09-23 | 2010-12-02 | The University Of Melbourne | Antigenic complex for the diagnosis and treatment of Porphyromonas gingivalis infection |
US9157914B2 (en) | 2006-01-10 | 2015-10-13 | Colgate-Palmolive Company | Methods of modulating cell surface receptors to prevent or reduce inflammation |
WO2019075260A1 (en) * | 2017-10-12 | 2019-04-18 | Sutrovax, Inc. | Periodontitis vaccine and related compositions and method of use |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0735293U (en) * | 1993-12-10 | 1995-06-27 | 株式会社松島製作所 | Lighting equipment |
AUPN627595A0 (en) * | 1995-10-30 | 1995-11-23 | University Of Melbourne, The | Diagnostics and treatments of periodontal disease |
US20030157637A1 (en) * | 1998-09-15 | 2003-08-21 | The University Of Melbourne | Diagnostics and treatments of periodontal disease |
US8129500B2 (en) * | 1997-12-10 | 2012-03-06 | Csl Limited | Porphyromonas gingivalis polypeptides and nucleotides |
SE0400191D0 (en) * | 2004-01-30 | 2004-01-30 | Tendera Ab | A test kit for detecting periodontal disease |
US20100092471A1 (en) | 2006-06-27 | 2010-04-15 | Oral Health Australia Pty Ltd | Porphyromonas Gingivalis Polypeptides Useful in the Prevention of Periodontal Disease |
ES2714008T3 (en) | 2007-07-12 | 2019-05-24 | Oral Health Australia Pty Ltd | Biofilm Treatment |
NZ595378A (en) | 2007-07-12 | 2013-04-26 | Immunology treatment for biofilms | |
US8140041B2 (en) * | 2009-08-27 | 2012-03-20 | Mediatek Inc. | Tunable capacitive device with linearization technique employed therein |
MY162557A (en) | 2010-02-26 | 2017-06-15 | Oral Health Australia Pty Ltd | Treatment or prevention of infection |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007286A1 (en) * | 1993-09-10 | 1995-03-16 | University Of Georgia Research Foundation, Inc. | Porphyromonas gingivalis arginine-specific proteinase coding sequences |
WO1995011298A1 (en) * | 1993-10-21 | 1995-04-27 | University Of Georgia Research Foundation, Inc. | Porphyromonas gingivalis lysine-specific proteinase |
AU4515196A (en) * | 1994-12-09 | 1996-06-26 | University Of Florida | Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5711937A (en) * | 1993-06-28 | 1998-01-27 | Lion Corporation | Oral composition |
US5523390A (en) * | 1993-09-10 | 1996-06-04 | University Of Georgia Research Foundation, Inc. | Porphyromonas gingivalis arginine-specific proteinase |
AUPN627595A0 (en) * | 1995-10-30 | 1995-11-23 | University Of Melbourne, The | Diagnostics and treatments of periodontal disease |
AUPO652897A0 (en) * | 1997-04-30 | 1997-05-29 | University Of Melbourne, The | Synthetic peptide constructs for the diagnosis and treatment of periodontitis |
-
1995
- 1995-10-30 AU AUPN6275A patent/AUPN627595A0/en not_active Abandoned
-
1996
- 1996-10-30 US US09/066,330 patent/US6511666B1/en not_active Expired - Lifetime
- 1996-10-30 EP EP96934198A patent/EP0858504B1/en not_active Expired - Lifetime
- 1996-10-30 JP JP51691597A patent/JP4117026B2/en not_active Expired - Fee Related
- 1996-10-30 DK DK96934198T patent/DK0858504T3/en active
- 1996-10-30 DE DE69635582T patent/DE69635582T2/en not_active Expired - Lifetime
- 1996-10-30 WO PCT/AU1996/000673 patent/WO1997016542A1/en active IP Right Grant
- 1996-10-30 NZ NZ320015A patent/NZ320015A/en not_active IP Right Cessation
- 1996-10-30 AT AT96934198T patent/ATE312909T1/en active
- 1996-10-30 ZA ZA969130A patent/ZA969130B/en unknown
- 1996-10-30 ES ES96934198T patent/ES2255082T3/en not_active Expired - Lifetime
- 1996-10-30 KR KR1019980703117A patent/KR100286055B1/en not_active IP Right Cessation
- 1996-10-30 AU AU72673/96A patent/AU715456B2/en not_active Ceased
-
2007
- 2007-01-18 US US11/654,512 patent/US20070189982A1/en not_active Abandoned
-
2011
- 2011-03-16 US US13/064,286 patent/US20110213129A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007286A1 (en) * | 1993-09-10 | 1995-03-16 | University Of Georgia Research Foundation, Inc. | Porphyromonas gingivalis arginine-specific proteinase coding sequences |
WO1995011298A1 (en) * | 1993-10-21 | 1995-04-27 | University Of Georgia Research Foundation, Inc. | Porphyromonas gingivalis lysine-specific proteinase |
AU4515196A (en) * | 1994-12-09 | 1996-06-26 | University Of Florida | Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease |
Non-Patent Citations (7)
Title |
---|
ADUSE-OPOKU J, ET AL.: "CHARACTERIZATION, GENETIC ANALYSIS AND EXPRESSION OF A PROTEASE ANTIGEN (PRPRI) OF PORPHYROMONAS GINGIVALIS W50", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 63, no. 12, 1 December 1995 (1995-12-01), US, pages 4744 - 4754, XP002951437, ISSN: 0019-9567 * |
BARKOCY-GALLAGHER G A, ET AL.: "ANALYSIS OF THE PRTP GENE ENCODING PORPHYPAIN, A CYSTEINE PROTEINASE OF PORPHYROMONAS GINGIVALIS", JOURNAL OF BACTERIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 178, no. 10, 1 May 1996 (1996-05-01), US, pages 2734 - 2741, XP002951436, ISSN: 0021-9193 * |
OKAMOTO K, ET AL.: "CLONING AND SEQUENCING OF THE GENE ENCODING A NOVEL LYSINE-SPECIFICCYSTEINE PROTEINASE (LYS-GINGIPAIN) IN PORPHYROMONAS GINGIVALIS: STRUCTURAL RELATIONSHIP WITH THE ARGININE-SPECIFIC CYSTEINE PROTEINASE (ARG-GINGIPAIN)", JOURNAL OF BIOCHEMISTRY, OXFORD UNIVERSITY PRESS, GB, vol. 120, no. 02, 1 January 1996 (1996-01-01), GB, pages 398 - 406, XP000973918, ISSN: 0021-924X * |
OKAMOTO K, ET AL.: "STRUCTURAL CHARACTERIZATION OF ARGINGIPAIN, A NOVEL ARGININE-SPECIFIC CYSTEINE PROTEINASE AS A MAJOR PERIODONTAL PATHOGENIC FACTOR FROM PORPHYROMONAS GINGIVALIS", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, ACADEMIC PRESS, US, vol. 316, no. 02, 1 February 1995 (1995-02-01), US, pages 917 - 925, XP000990888, ISSN: 0003-9861, DOI: 10.1006/abbi.1995.1123 * |
PAVLOFF N., ET AL.: "MOLECULAR CLONING AND STRUCTURAL CHARACTERIZATION OF THE ARG-GINGIPAIN PROTEINASE OF PORPHYROMONAS GINGIVALIS. ÖBIOSYNTHESIS AS A PROTEINASE ADHESIN POLYPROTEIN.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 270., no. 03., 20 January 1995 (1995-01-20), US, pages 1007 - 1010., XP000606026, ISSN: 0021-9258, DOI: 10.1074/jbc.270.3.1007 * |
PIKE R., ET AL.: "LYSINE- AND ARGININE-SPECIFIC PROTEINASES FROM PORPHYROMONAS GINGIVALIS.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 269., no. 01., 7 January 1994 (1994-01-07), US, pages 406 - 411., XP000606021, ISSN: 0021-9258 * |
SLAKESKI N, CLEAL S, REYNOLDS E C: "CHARACTERIZATION OF A PORPHYROMONAS GINGIVALIS GENE PRTR THAT ENCODES AN ARGININE-SPECIFIC THIOL PROTEINASE AND MULTIPLE ADHESINS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 224, 1 January 1996 (1996-01-01), US, pages 605 - 610, XP002951441, ISSN: 0006-291X, DOI: 10.1006/bbrc.1996.1073 * |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7262271B2 (en) | 1997-04-30 | 2007-08-28 | Csl Limited | Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with Porphyromonas gingivalis |
US7749502B2 (en) | 1997-04-30 | 2010-07-06 | The University Of Melbourne | Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with Porphyromonas gingivalis |
US8841420B2 (en) | 1997-04-30 | 2014-09-23 | The University Of Melbourne | Synthetic peptide constructs for the diagnosis and treatment of periodontis associated with Porphyromonas gingivalis |
US8431688B2 (en) | 1997-04-30 | 2013-04-30 | The University Of Melbourne | Synthetic peptide constructs for the diagnosis and treatment of Periodontitis associated with Porphyromonas gingivalis |
EP1985625A2 (en) | 1997-04-30 | 2008-10-29 | CSL Limited | Synthetic peptide constructs for the diagnosis and treatment of periodontitus associated with porphyromonas gingivalis |
WO1998049192A1 (en) * | 1997-04-30 | 1998-11-05 | The University Of Melbourne | SYNTHETIC PEPTIDE CONSTRUCTS FOR THE DIAGNOSIS AND TREATMENT OF PERIODONTITIS ASSOCIATED WITH $i(PORPHYROMONAS GINGIVALIS) |
EP2283855A3 (en) * | 1997-12-10 | 2011-05-04 | CSL Limited | Polypeptides et polynucleotides de phorphorymonas gingivalis |
EP2283854A3 (en) * | 1997-12-10 | 2011-04-06 | CSL Limited | Porphorymonas gingivalis polypeptides and polynucleotides |
EP2283853A3 (en) * | 1997-12-10 | 2011-05-11 | CSL Limited | Porphorymonas gingivalis polypeptides and polynucleotides |
EP2283852A3 (en) * | 1997-12-10 | 2011-05-04 | CSL Limited | Porphorymonas gingivalis polypeptides and polynucleotides |
EP2256205A1 (en) * | 1997-12-10 | 2010-12-01 | CSL Limited | Porphorymonas gingivalis polypeptides and polynucleotides |
EP2256204A1 (en) * | 1997-12-10 | 2010-12-01 | CSL Limited | Porphorymonas gingivalis polypeptides and polynucleotides |
EP1908772A2 (en) | 1997-12-10 | 2008-04-09 | Csl Limited | Porphorymonas gingivalis polypeptides and polynucleotides |
JP2009136300A (en) * | 1997-12-10 | 2009-06-25 | Csl Ltd | Porphorymonas gingivalis polypeptide and nucleotide |
EP1908772A3 (en) * | 1997-12-10 | 2008-12-03 | Csl Limited | Porphorymonas gingivalis polypeptides and polynucleotides |
EP2264176A1 (en) * | 1997-12-10 | 2010-12-22 | CSL Limited | Porphorymonas gingivalis polypeptides and polynucleotides |
US6652875B1 (en) | 1998-07-29 | 2003-11-25 | Pacific Biolink Pty. Limited | Casein formulations for the delivery of bioactive constituents |
JP2003520765A (en) * | 1999-03-01 | 2003-07-08 | ザ・ユニヴァーシティ・オブ・メルボーン | Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis by Porphyromonas gingivalis |
EP1157033A4 (en) * | 1999-03-01 | 2005-06-15 | Univ Melbourne | Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis |
EP1157033A1 (en) * | 1999-03-01 | 2001-11-28 | The University Of Melbourne | Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis |
US8282933B2 (en) | 1999-12-24 | 2012-10-09 | Csl Limited | P. gingivalis antigenic composition |
JP2011120581A (en) * | 1999-12-24 | 2011-06-23 | Csl Ltd | P. gingivalis antigenic composition |
EP1240191A1 (en) * | 1999-12-24 | 2002-09-18 | Csl Limited | P. gingivalis antigenic composition |
US8784831B2 (en) * | 1999-12-24 | 2014-07-22 | Csl Limited | P. gingivalis antigenic composition |
EP1985626A1 (en) | 1999-12-24 | 2008-10-29 | CSL Limited | P. gingivalis antigenic composition |
US7419671B2 (en) | 1999-12-24 | 2008-09-02 | Csl Limited | P. gingivalis antigenic composition |
EP2243789A1 (en) * | 1999-12-24 | 2010-10-27 | CSL Limited | P.gingivalis antigenic composition |
JP2003518932A (en) * | 1999-12-24 | 2003-06-17 | シーエスエル、リミテッド | P. gingivalis antigen composition |
EP1240191A4 (en) * | 1999-12-24 | 2005-07-06 | Csl Ltd | P. gingivalis antigenic composition |
US7204991B2 (en) | 2000-04-28 | 2007-04-17 | Csl Limited | Porphyromonas gingivalis recombinant proteins and truncations |
JP2003531634A (en) * | 2000-04-28 | 2003-10-28 | シーエスエル、リミテッド | Porphyromonas gingivalis recombinant protein and truncated product |
WO2006032104A1 (en) | 2004-09-23 | 2006-03-30 | The University Of Melbourne | Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection |
US8765144B2 (en) | 2004-09-23 | 2014-07-01 | The University Of Melbourne | Antigenic complex for the diagnosis and treatment of Porphyromonas gingivalis infection |
AU2005287884B2 (en) * | 2004-09-23 | 2010-12-02 | The University Of Melbourne | Antigenic complex for the diagnosis and treatment of Porphyromonas gingivalis infection |
US9157914B2 (en) | 2006-01-10 | 2015-10-13 | Colgate-Palmolive Company | Methods of modulating cell surface receptors to prevent or reduce inflammation |
WO2010022463A1 (en) * | 2008-08-29 | 2010-03-04 | Oral Health Australia Pty Ltd | Prevention, treatment and diagnosis of p.gingivalis infection |
US10851138B2 (en) | 2008-08-29 | 2020-12-01 | Oral Health Australia Pty Ltd | Methods of preparing P. gingivalis antibodies |
US11572391B2 (en) | 2008-08-29 | 2023-02-07 | Oral Health Australia Pty Ltd | Antibodies for prevention, treatment and diagnosis of P. gingivalis infection |
WO2019075260A1 (en) * | 2017-10-12 | 2019-04-18 | Sutrovax, Inc. | Periodontitis vaccine and related compositions and method of use |
US10835590B2 (en) | 2017-10-12 | 2020-11-17 | Vaxcyte, Inc. | Periodontitis vaccine and related compositions and methods of use |
US11701414B2 (en) | 2017-10-12 | 2023-07-18 | Vaxcyte, Inc. | Periodontitis vaccine and related compositions and methods of use |
Also Published As
Publication number | Publication date |
---|---|
JP4117026B2 (en) | 2008-07-09 |
US20070189982A1 (en) | 2007-08-16 |
EP0858504B1 (en) | 2005-12-14 |
AU7267396A (en) | 1997-05-22 |
DE69635582T2 (en) | 2006-08-17 |
EP0858504A4 (en) | 2002-12-04 |
KR19990067167A (en) | 1999-08-16 |
JP2000510817A (en) | 2000-08-22 |
DE69635582D1 (en) | 2006-01-19 |
KR100286055B1 (en) | 2001-05-02 |
NZ320015A (en) | 1999-02-25 |
ZA969130B (en) | 1997-06-24 |
US6511666B1 (en) | 2003-01-28 |
DK0858504T3 (en) | 2006-02-13 |
US20110213129A1 (en) | 2011-09-01 |
EP0858504A1 (en) | 1998-08-19 |
ES2255082T3 (en) | 2006-06-16 |
AU715456B2 (en) | 2000-02-03 |
AUPN627595A0 (en) | 1995-11-23 |
ATE312909T1 (en) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070189982A1 (en) | Diagnostics and treatments of Periodontal disease | |
US8784831B2 (en) | P. gingivalis antigenic composition | |
US8765144B2 (en) | Antigenic complex for the diagnosis and treatment of Porphyromonas gingivalis infection | |
EP0954529B1 (en) | Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis | |
US20030157637A1 (en) | Diagnostics and treatments of periodontal disease | |
CA2235224C (en) | Diagnostics and treatments of periodontal disease | |
AU2005287884B2 (en) | Antigenic complex for the diagnosis and treatment of Porphyromonas gingivalis infection | |
AU713844B2 (en) | Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis | |
AU775228B2 (en) | P. gingivalis antigenic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR NZ SG US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2235224 Country of ref document: CA Kind code of ref document: A Ref document number: 2235224 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980703117 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996934198 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 320015 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1996934198 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09066330 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980703117 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019980703117 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996934198 Country of ref document: EP |